Dianthus Therapeutics, Inc. — Net Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/48daafea-3818-4ab8-a9a4-0f5e28cc9ffd/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-162.3M | 2025-01-01 – 2025-12-31 | evidence 0001690585-26-000006 |
| FY 2024 | $-85.0M | 2024-01-01 – 2024-12-31 | evidence 0000950170-25-037131 |
| FY 2023 | $-43.5M | 2023-01-01 – 2023-12-31 | evidence 0001690585-26-000012 |
| FY 2022 | $-28.5M | 2022-01-01 – 2022-12-31 | evidence 0001193125-23-301206 |
| FY 2021 | $-13.1M | 2021-01-01 – 2021-12-31 | evidence 0001193125-23-301206 |
| FY 2020 | $-74.9M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-152654 |
| FY 2019 | $-76.8M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-135615 |
| FY 2018 | $-57.5M | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-142296 |
| FY 2017 | $-35.5M | 2017-01-01 – 2017-12-31 | evidence 0001193125-19-078948 |
| FY 2016 | $-9.4M | 2016-01-01 – 2016-12-31 | evidence 0001193125-19-078948 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Dianthus Therapeutics, Inc. — all facts · Revenue · Operating Income